The effectiveness of different treatment options for non‐islet cell tumour hypoglycaemia
- 25 March 2004
- journal article
- case report
- Published by Wiley in Clinical Endocrinology
- Vol. 60 (4), 457-460
- https://doi.org/10.1111/j.1365-2265.2004.01989.x
Abstract
Objective To compare the outcome of different treatment options used in several cases of non‐islet cell tumour hypoglycaemia (NICTH). patients Eight cases of NICTH were referred for diagnosis and monitoring following either surgical or medical treatment. methods Serum samples collected throughout the time‐course of each case were analysed for glucose, insulin, C‐peptide, IGF‐I, total IGF‐II, total IGF‐II to IGF‐I ratio and, in most of the cases, big IGF‐II. results Surgical excision was successful in the relief of symptoms and normalization of the biochemical parameters. Therapeutic treatment with glucocorticoids confirmed previous studies showing the suppressive effect on tumour (big) IGF‐II production. The present data show that the effect was dose‐dependent and reversible if doses were below a critical level. conclusions Within the limits of the cases studied, and the time‐scales involved, moderate‐ to high‐dose glucocorticoid therapy had immediate beneficial influence on symptomatic hypoglycaemia and, if tolerated in the long term, was effective in correcting the underlying biochemical dysfunction, unlike other therapeutic regimens. This effectiveness was only achieved when the dose exceeded a threshold level specific to the patient. In addition, reduction of the dose or withdrawal of the drug caused a return of the abnormal biochemical profile. Surgical removal of the malignancy, where this was an option, was successful within the periods studied.Keywords
This publication has 12 references indexed in Scilit:
- The role of the growth hormone–insulin‐like growth factor axis in glucose homeostasisDiabetic Medicine, 2003
- Tumor Hypoglycemia Linked to IGF-IIPublished by Springer Science and Business Media LLC ,1999
- Gene expression and serum levels of insulin-like growth factors (IGFs) and IGF-binding proteins in a case of non-islet cell tumour hypoglycaemiaGrowth Hormone & IGF Research, 1998
- Glucocorticoid therapy suppresses abnormal secretion of big IGF‐II by non‐islet cell tumours inducing hypoglycaemia (NICTH)Clinical Endocrinology, 1998
- Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemiaJournal of Clinical Endocrinology & Metabolism, 1995
- Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.Proceedings of the National Academy of Sciences of the United States of America, 1993
- Impaired Formation of the Ternary Insulin-Like Growth Factor-Binding Protein Complex in Patients with Hypoglycemia due to Nonislet Cell Tumors*Journal of Clinical Endocrinology & Metabolism, 1991
- Differential Effects of Prednisone and Growth Hormone on Fuel Metabolism and Insulin Antagonism in HumansDiabetes, 1991
- Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.JCI Insight, 1981
- Measurement of Insulin-Like Growth Factor II by a Specific Radioreceptor Assay in Serum of Normal Individuals, Patients with Abnormal Growth Hormone Secretion, and Patients with Tumor-Associated Hypoglycemia*Journal of Clinical Endocrinology & Metabolism, 1981